Argus analyst John Staszak resumed Herbalife Nutrition with a Buy rating and a price target of $72, saying the company stands to benefit from "increased consumer interest in overall health and fitness, rather than just weight-loss products." The analyst is positive on the company's efforts to expand its product portfolio in capitalizing on that trend and relying more on coaching and educational programs to boost sales. Staszak further states that Herbalife's 2016 settlement with the FTC has likely resolved most of its legal and regulatory hurdles.